Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-05-07 |
2024-03 |
-0.35 |
-0.33 |
0.02 |
5.71% |
2024-02-14 |
2023-12 |
-0.32 |
N/A |
N/A |
N/A |
2024-02-14 |
2023-12 |
-0.32 |
-0.3 |
0.02 |
6.25% |
2023-11-09 |
2023-09 |
-0.32 |
-0.35 |
-0.03 |
-9.38% |
2023-11-09 |
2023-09 |
-0.32 |
N/A |
N/A |
N/A |
2023-08-02 |
2023-06 |
-0.33 |
N/A |
N/A |
N/A |
Date |
Firm |
Action |
From |
To |
2023-10-15 |
Piper Sandler |
Upgrade |
Overweight |
Overweight |
2023-08-07 |
Piper Sandler |
Upgrade |
Overweight |
Overweight |
2023-08-03 |
Morgan Stanley |
Upgrade |
Equal-Weight |
Equal-Weight |
2023-05-04 |
Morgan Stanley |
Upgrade |
|
Equal-Weight |
2023-02-15 |
Morgan Stanley |
Upgrade |
|
Equal-Weight |
2023-02-14 |
Credit Suisse |
Upgrade |
|
Underperform |
Date |
Name |
Relation |
Quantity |
Description |
2024-03-04 |
BENZENO SHARON |
Officer |
327.42K |
Sale |
2024-03-04 |
BOBULSKY SUSAN |
Officer |
248.29K |
Sale |
2024-03-03 |
GRIFFIN MICHELLE RENEE |
Director |
51.96K |
Stock Award(Grant) |
2024-03-04 |
LO FRANCIS |
Officer |
256.25K |
Sale |
2024-03-11 |
NEUPERT PETER M |
Director |
169.30K |
Conversion of Exercise of derivative security |
2024-03-04 |
PETERSON TYCHO |
Chief Financial Officer |
531.55K |
Sale |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Viking Global Investors, L.P. |
29.99M |
201.26M |
20.74% |
2023-06-29 |
Vanguard Group Inc |
12.05M |
80.87M |
8.33% |
2023-06-29 |
Matrix Capital Management |
11.57M |
77.65M |
8.00% |
2023-09-29 |
ARK Investment Management, LLC |
11.51M |
62.73M |
7.96% |
2023-06-29 |
Blackrock Inc. |
11.48M |
77.05M |
7.94% |
2023-06-29 |
Nikko Asset Management Americas, Inc. |
6.38M |
42.84M |
4.41% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-09-29 |
ARK ETF Tr-ARK Genomic Revolution ETF |
11.41M |
62.17M |
7.89% |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
3.94M |
26.43M |
2.72% |
2023-06-29 |
Vanguard Small-Cap Index Fund |
3.35M |
22.50M |
2.32% |
2023-08-30 |
iShares Russell 2000 ETF |
2.61M |
17.68M |
1.81% |
2023-06-29 |
Vanguard Small-Cap Growth Index Fund |
1.92M |
12.89M |
1.33% |
2023-06-29 |
Vanguard Extended Market Index Fund |
1.54M |
10.33M |
1.06% |